glp-1 review article A new by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, describes a new generation of treatment with receptor agonists for persons with obesity with or without diabetes or Frontiers | Dissecting the Physiology
Description
Without an on-label indication for T1D, GLP-1s remain costly and out of reach for most
Food and Drug Administration: 2019 [cited 2021 Jan 25]
There have been no head-to-head studies comparing the weight loss results of the weekly injection to the daily tablet formulation
PMID: 73 KanwalF
